SCHEMBL744132

SCHEMBL744132

Fc1cccc2scnc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.46
ALDH1A1 P00352 6/20 0.45
HSD17B10 Q99714 1/20 0.45
RAB9A P51151 7/20 0.44
NPC1 O15118 6/20 0.44
MEN1 O00255 4/20 0.44
HPGD P15428 4/20 0.44
KMT2A Q03164 4/20 0.44
GAA P10253 3/20 0.44
KDM4E B2RXH2 3/20 0.44
LMNA P02545 3/20 0.44
PRNP P04156 1/20 0.44
MAPT P10636 3/20 0.42
L3MBTL1 Q9Y468 1/20 0.39
CASP3 P42574 2/20 0.38
SENP8 Q96LD8 2/20 0.38
SENP7 Q9BQF6 2/20 0.38
SENP6 Q9GZR1 2/20 0.38
MAPK1 P28482 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzene SCHEMBL27538848 0.98 SMN1; SMN2 (0.44) SMN1; SMN2ALDH1A1HSD17B10RAB9ANPC1
Hydrazine SCHEMBL27575629 0.96 SMN1; SMN2 (0.47) SMN1; SMN2ALDH1A1HSD17B10RAB9ANPC1
SCHEMBL29737639 0.74 PDPK1 (0.46) ALDH1A1HSD17B10RAB9AHPGDKMT2A
SCHEMBL2682744 0.74 ALDH1A1 (0.45) SMN1; SMN2ALDH1A1HSD17B10RAB9ANPC1
SCHEMBL29967087 0.74 ALDH1A1 (0.46) SMN1; SMN2ALDH1A1HSD17B10RAB9ANPC1
SCHEMBL288904 0.74 ALDH1A1 (0.46) SMN1; SMN2ALDH1A1HSD17B10RAB9ANPC1
SCHEMBL2088376 0.74 ALDH1A1 (0.45) ALDH1A1HSD17B10RAB9ANPC1KDM4E
SCHEMBL197613 0.74 ALDH1A1 (0.45) ALDH1A1HSD17B10MAPTL3MBTL1HTR1A
SCHEMBL926998 0.74 LMNA (0.46) SMN1; SMN2ALDH1A1HSD17B10RAB9ANPC1
SCHEMBL288903 0.74 ALDH1A1 (0.45) ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3972596-B1 COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES PFIZER (US) 2025-07-16 EP claimed
EP-3704113-B1 BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS BRISTOL MYERS SQUIBB CO (US) 2023-10-11 EP claimed
WO-2023059867-A1 COMPOUNDS FOR TREATING OR PREVENTING ALZHEIMER'S DISEASE THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-04-13 WO claimed
EP-3704114-B1 SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS BRISTOL MYERS SQUIBB CO (US) 2022-11-23 EP claimed
EP-3681881-B1 HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS ARDELYX INC (US) 2022-11-02 EP claimed
CN-111632594-A Method for regulating and controlling surface plasmon photocatalysis and application 南京工业大学 2020-09-08 CN claimed
US-10224485-B2 Process for preparing a crystalline organic semiconductor material BASF SE (DE) 2019-03-05 US claimed
US-20170012208-A1 ORGANIC SEMICONDUCTOR FORMULATIONS USINVEST LLC 2017-01-12 US claimed
US-12545671-B2 Compound having biological activity such as antiviral activity NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE (JP) 2026-02-10 US disclosed
US-20250320201-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS INC (US) 2025-10-16 US disclosed
US-20250171438-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS, INC. 2025-05-29 US disclosed
CN-119798326-A Benzothiazole phosphorus compound and synthetic method and application thereof 江西师范大学 2025-04-11 CN disclosed
US-20240246951-A1 COMPOUND HAVING BIOLOGICAL ACTIVITY SUCH AS ANTIVIRAL ACTIVITY NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE (JP) 2024-07-25 US disclosed
EP-3183250-B1 PROCESS FOR PREPARING CRYSTALLINE ORGANIC SEMICONDUCTOR MATERIAL CLAP CO LTD (KR) 2023-10-04 EP disclosed
US-5861424-A CATIONIC HETEROCYCLIC COMPOUNDS FOR TREATING CANCER DANA FARBER CANCER INSTITUTE (US) 1999-01-19 US disclosed
US-5670530-A ADJUSTMENT SOLUBILITY OF RHODACYANINE COMPOUND FUJI PHOTO FILM CO., LTD. (JP) 1997-09-23 US disclosed
EP-0527494-B1 Compositon containing rhodacyanine dyes for treating cancer FUJI PHOTO FILM CO LTD (JP) 1996-11-06 EP disclosed
US-5360803-A Rhodocyanine dyes DAN FARBER CANCER INSTITUTE (US) 1994-11-01 US disclosed
CN-1071834-A The compositions and the method for treatment cancer FUJI PHOTO FILM CO LTD (JP) 1993-05-12 CN disclosed
EP-0527494-A1 Compositon containing rhodacyanine dyes for treating cancer Fuji Photo Film Co., Ltd. (JP) 1993-02-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545671-B2 Compound having biological activity such as antiviral activity SARS1, ACE2, ACE SMN1; SMN2 1097/4885ALDH1A1 2867/4885HSD17B10 2602/4885
US-20240246951-A1 COMPOUND HAVING BIOLOGICAL ACTIVITY SUCH AS ANTIVIRAL ACTIVITY RNASE1, ZC3HAV1, ACE SMN1; SMN2 2652/4885ALDH1A1 1459/4885HSD17B10 2409/4885
US-20250320201-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS PAH, KDM8, PHF8 SMN1; SMN2 1592/4885ALDH1A1 865/4885HSD17B10 1477/4885
US-10224485-B2 Process for preparing a crystalline organic semiconductor material STOM, SPOP, TTR SMN1; SMN2 4265/4885ALDH1A1 4757/4885HSD17B10 4363/4885
US-20250171438-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS PAH, KDM8, PHF8 SMN1; SMN2 1592/4885ALDH1A1 865/4885HSD17B10 1477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.